FUNDAMENTALS |
MarketCap: |
249.63 mill
|
EPS: |
-1.080
|
P/E: |
-0.0100
|
Earnings Date: |
Mar 19, 2024 |
SharesOutstanding: |
15 602 mill
|
Avg Daily Volume: |
0 mill
|
RATING
2024-01-16 |
B-
|
Neutral
|
RATINGS |
Rating CashFlow: |
Neutral
|
|
Return On Equity: |
Strong Buy
|
|
Return On Asset: |
Sell
|
|
DE: |
Strong Sell
|
|
P/E: |
Neutral
|
|
Price To Book: |
Strong Sell
|
|
QUARTER GROWTHS |
|
1/22 | 2/22 | 3/22 | 4/22 | 1/23 | 2/23 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
0.00x
|
Company: PE -0.0100 | sector: PE -3.05
|
PE RATIO: COMPANY / INDUSTRY |
0.00x
|
Company: PE -0.0100 | industry: PE 18.71
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 0.0010 - 0.0290
( +/- 93.33%)
|
ATR Model: 14 days
|
Forecast:
01:40 - $-0.0140
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$0.0160 (0.00% )
|
Volume |
120.55 mill
|
Avg. Vol. |
0 mill
|
% of Avg. Vol |
0 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For LMDX
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.